Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IL13Ralpha2 hinge-optimized 41BB CAR truncated CD19-expressing autologous T-cells
- Development stage
- Phase 1
- Lead developer
- Mustang Bio
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intratumoral, Intraventricular
01
Overview
IL13Ralpha2 hinge-optimized 41BB CAR truncated CD19-expressing autologous T-cells is a cellular immunotherapy that uses a patient's own T cells, which are genetically modified to express a chimeric antigen receptor (CAR) targeting IL13Rα2, a protein frequently overexpressed in glioblastoma and other malignant brain tumors. The therapy incorporates a 4-1BB (CD137) co-stimulatory domain for improved T cell persistence and anti-tumor activity, along with a truncated CD19 marker for cell tracking. The CAR has been designed with an optimized hinge region to enhance binding to IL13Rα2 on tumor cells while minimizing binding to IL13Rα1, which is more widely expressed in normal tissues. This therapy is administered locoregionally (intratumoral and/or intraventricular) to patients with recurrent or refractory malignant brain tumors.
- Brand names
- MB-101MB101MB 101
- Other names
- IL13Rα2-targeted CAR T cellsIL13Rα2-CAR T cellsIL13BBζ T cells
02
Targets
IL13RA2 (Interleukin-13 receptor subunit alpha 2)
Beyond the preview
Go deeper on IL13Ralpha2 hinge-optimized 41BB CAR truncated CD19-expressing autologous T-cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IL13Ralpha2 hinge-optimized 41BB CAR truncated CD19-expressing autologous T-cells.